Cord blood cells engineered to fight deadly mold in first human test

NCT ID NCT07454122

Not yet recruiting Disease control Sponsor: Fundacion Clinic per a la Recerca Biomédica Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a new approach for patients with invasive mold infections that are not responding to standard antifungal medicines. Researchers take natural killer (NK) cells from donated umbilical cord blood and genetically modify them to better target the mold. The study will enroll 10 adults to see if the treatment is safe and tolerable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: genetically modified natural killer (NK) cells from umbilical cord blood
What this could lead to: If it works, this could offer a new treatment option for people with severe mold infections that don't respond to standard antifungal drugs.
What could go wrong: This is a very early, small phase 1 trial with only 10 participants, so it's mainly checking safety. It may not work, and there could be serious side effects from the cell infusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FUNGAL INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fungal infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FUNGAL INFECTION

Contacts and locations

Locations

Hospital Clinic Barcelona

Barcelona, Barcelona, 08036, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.